GLP-1 blockbusters like semaglutide and tirzepatide are widely used for diabetes and weight loss but come with some nasty ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer ...

TCG Labs Soleil has secured $400 million to boost the firm’s ability to advance its biotech portfolio companies while also expanding its R&D capabilities globally. | TCG Labs Soleil has secured $400 ...

The phase 3 trial randomized 260 people with anti-acetylcholine receptor antibody-positive gMG to take gefurulimab or placebo. After 26 weeks, people on gefurulimab performed significantly better on a ...

Roche has axed one of the obesity assets from its $2.7 billion Carmot Therapeutics buyout, sending the molecule to the scrap heap months after hyping its potential to drive weight loss past the GLP-1 ...

Boston Scientific bumped up its financial forecasts for the remainder of this year after reporting double-digit growth across ...

Arrowhead Pharmaceuticals has moved to reassure Wall Street about its deal with Sarepta Therapeutics, telling investors that ...

The FDA is spotlighting a new medical device correction effort at Baxter over its large-volume Novum IQ infusion pump, ...

Roche’s Flatiron Health is celebrating a milestone. Over the last year, the company has tripled the size of its international ...

Genentech has executed another round of layoffs, eliminating 87 positions at its headquarters in South San Francisco. | Genentech has executed another round of layoffs, eliminating 87 positions at its ...

Dispatch Bio has unveiled with $216 million and the lofty goal of creating a universal treatment for solid tumors using a new ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...